期刊论文详细信息
Antibodies
Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
May Lin Helen Oh1  Tar Choon Aw2  Soon Kieng Phua2  Ya Li Liang2  Chin Shern Lau2  Yanfeng Li3  Shengli Xu4  Jianxin Huo4  Yuhan Huang4  Biyan Zhang4 
[1] Department of Infectious Diseases, Changi General Hospital, Singapore 529889, Singapore;Department of Laboratory Medicine, Changi General Hospital, Singapore 529889, Singapore;GenScript Biotech (Singapore) Pte Ltd., Singapore 349248, Singapore;Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore;
关键词: mRNA vaccine;    inactivated virus vaccine;    antibodies;    SARS-CoV-2;   
DOI  :  10.3390/antib11020038
来源: DOAJ
【 摘 要 】

Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees over a 14-month period from January 2021 to February 2022. All vaccinees received three doses of one type of vaccine. Antibody levels (Roche Elecsys total S-Ab and the Snibe N-Ab) were tested 10 days after the first dose, 20 days after the second dose, and 20 days after the booster dose. Results: At all time points, the mRNA vaccine generated higher S-Ab and N-Ab responses than the inactivated virus vaccine (S-Ab: first dose 2.48 vs. 0.4 BAU/mL, second dose 2174 vs. 98 BAU/mL, third dose 15,004 vs. 525 BAU/mL; N-Ab: first dose 0.05 vs. 0.02 µg/mL, second dose 3.48 vs. 0.38 µg/mL, third dose 19.8 vs. 0.89 µg/mL). mRNA vaccine recipients had a 6.2/22.2/28.6-fold higher S-Ab and 2.5/9.2/22.2-fold higher N-Ab response than inactivated virus vaccine recipients after the first/second/third inoculations, respectively. Mann–Whitney U analysis confirmed the significant difference in S-Ab and N-Ab titers between vaccination groups at each time point. Conclusions: The mRNA vaccines generated a more robust S-Ab and N-Ab response than the inactivated virus vaccine at all time points after the first, second, and third vaccinations.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次